Anti-eAg Antibody from X63 Fused CD19 B Cell Hybridoma (D4)
Invented by Anders Elm Pedersen , Mogens H Claesson
Invented at University of Copenhagen
- References (1)
- Inventor Info
|Antigen/Gene or Protein Targets||Enteroantigen|
Regulatory B cells (Bregs) have been shown to play a role in inflammatory bowel disease (IBD) in humans, as B cell depletion in patients with IBD tends to aggravate the disease. Furthermore it has been demonstrated that co-transfer of eAg-exposed B cells improves symptoms of experimental colitis in the T cell transfer model of colitis.
This eAg-specific B cell hybridoma offers a unique tool to investigate the immune response towards eAg’s in experimental colitis, and potentially, in human IBD.
|Notes||Hybridoma cell lines profit from the addition of 10 ng/ml of human IL-6 in the growth media.|
There are 1 reference entries for this reagent.View All References
Anders Elm Pedersen
Mogens H Claesson